Clinical Trials Logo
  1. Home
  2. Guillain-Barre Syndrome
  3. NCT02342184

Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome

Guillain-Barré Syndrome Clinical Trial

Official title:
Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome

Clinical Trial Summary

This study will carry out to assess the efficacy of GB-0998 (intravenous immunoglobulin;400mg/kg/day for five days) in the treatment of the Guillain-Barré Syndrome based on the changes in Hughes Functional Grade (FG) as primary endpoint, and in addition, to assess the safety of GB-0998.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02342184
Study type Interventional
Source Japan Blood Products Organization
Contact
Status Completed
Phase Phase 3
Start date August 2014
Completion date September 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT02221271 - Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Phase 3
Withdrawn NCT05494619 - A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) Phase 3
Withdrawn NCT03773328 - A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-BarreĢ Syndrome (GBS) Phase 1
Active, not recruiting NCT01582763 - International Guillain-Barré Syndrome Outcome Study
Completed NCT04035135 - A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) Phase 1
Recruiting NCT05461898 - RehabGBs: Rehabilitation in People With Guillain-Barré Syndrome N/A
Completed NCT02780570 - Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients Phase 2